Shares of Mankind Pharma surged by nearly 5% after global investment firm Investec initiated a “Buy” rating on the stock, with a target price of ₹3,300.
This represents a potential upside of approximately 35% from the stock’s previous close of ₹2,442. Investec’s bullish stance on the company has drawn significant attention from investors, driving the stock higher in early trading on Thursday.
Investec has highlighted Mankind Pharma’s potential to become a leader in innovation and high-barrier products. The brokerage report indicates that Mankind Pharma’s long-term strategy focuses on differentiation and building capabilities in specialty segments. The report emphasizes Mankind’s growing focus on creating innovative solutions that are difficult for competitors to replicate, thereby fortifying its leadership in the pharmaceutical industry.
According to Investec, Mankind Pharma’s collaboration with Bharat Serums and Vaccines (BSV) will play a pivotal role in the company’s growth strategy. BSV is known for its strong specialty R&D capabilities, and the partnership is expected to provide Mankind Pharma with an edge in specialty drugs and treatments. The brokerage firm believes that the synergies between Mankind Pharma’s extensive network and BSV’s specialty offerings will drive substantial growth, particularly in the Indian market, where demand for advanced healthcare solutions is rising.
One of the most significant growth drivers identified by Investec is the potential in the In Vitro Fertilization (IVF) market, which remains largely underpenetrated. The IVF market, valued at around $6 billion globally, offers a substantial opportunity for Mankind Pharma and BSV. With the partnership between these two companies, Investec believes that Mankind Pharma has the potential to become a global leader in the IVF space.
In addition to the IVF market, BSV’s focus on specialty products is seen as a long-term moat that the market currently underappreciates.
As of 9:24 AM, the stock was trading 4.85% higher at ₹2,544.05 on the NSE.
